Schönburg Sandra, Bauer Wilhelm, Mohammed Nasreldin, Brössner Clemens, Fornara Paolo
Department of Urology and Kidney Transplantation, Martin Luther University, Halle (Saale), Germany.
Department of Urology, Hospital Barmherzige Schwestern, Vienna, Austria.
Front Surg. 2019 Dec 17;6:72. doi: 10.3389/fsurg.2019.00072. eCollection 2019.
The urinary incontinence system ATOMS (A.M.I., Austria) generates suburethral compression through its sphincter cushion. To what extent the ATOMS may lead to overactive bladder (OAB) symptoms or which risk factors for these symptoms exist remain unknown to date. We report on our multicentre evaluation on the prevalence, status, and therapy of OAB after ATOMS. Between 10/09 and 01/17, a total of 361 patients received an ATOMS device in Vienna and Halle. A prerequisite for surgery was persistent male stress urinary incontinence lasting at least 6 months after the primary intervention, as well as the failure of conservative treatment. Patients with a preoperative untreated anastomotic stricture or detrusor overactivity were excluded. In addition to continence and voiding parameters, patient's age, BMI, comorbidities, and pre-treatment strategies of the underlying disease and urinary incontinence were examined. If OAB was present, urodynamics were used for further clarification. Statistical analysis was performed with GraphPad Prism 7® (GraphPad Software, Inc., La Jolla, USA), < 0.05 considered significant. OAB presented 18 patients (4.9%). Regarding the degree of urinary incontinence as well as uroflowmetry, residual volume and comorbidities, patients with an OAB showed no differences compared to patients without an OAB ( < 0.05). Only previous radiotherapy or urinary incontinence surgery and urethral stricture interventions resulted in statistically significant differences based on the bivariate analysis ( = 0.030, = 0.006, = 0.007). The consecutive postoperative urodynamics revealed a sensory OAB in 17 patients and a low-compliance bladder in a patient with newly diagnosed insulin-dependent type II diabetes mellitus. OAB was treated with a standard dose of antimuscarinic drugs and for the low-compliance bladder with botulinum toxin type A. OAB symptoms can occur after ATOMS implantation, but are rare and have no clear correlation to the incontinence device but rather are due to urinary incontinence-related underlying diseases and previous treatments.
尿失禁系统ATOMS(奥地利A.M.I.公司)通过其括约肌垫产生尿道下压迫。截至目前,ATOMS在多大程度上可能导致膀胱过度活动症(OAB)症状或这些症状存在哪些风险因素仍不清楚。我们报告了我们对ATOMS术后OAB的患病率、状况和治疗的多中心评估。在2009年10月至2017年1月期间,维也纳和哈雷共有361名患者接受了ATOMS装置。手术的一个前提条件是原发性干预后持续至少6个月的男性压力性尿失禁,以及保守治疗失败。术前未治疗的吻合口狭窄或逼尿肌过度活动的患者被排除在外。除了控尿和排尿参数外,还检查了患者的年龄、体重指数、合并症以及基础疾病和尿失禁的治疗前策略。如果存在OAB,则使用尿动力学进行进一步明确。使用GraphPad Prism 7®(美国拉霍亚GraphPad软件公司)进行统计分析,P<0.05被认为具有统计学意义。18名患者(4.9%)出现OAB。关于尿失禁程度以及尿流率、残余尿量和合并症,有OAB的患者与无OAB的患者相比无差异(P<0.05)。仅根据双变量分析,既往放疗或尿失禁手术以及尿道狭窄干预导致了统计学上的显著差异(P = 0.030、P = 0.006、P = 0.007)。连续的术后尿动力学检查显示,17名患者存在感觉性OAB,1名新诊断为胰岛素依赖型II型糖尿病的患者存在低顺应性膀胱。OAB用标准剂量的抗毒蕈碱药物治疗,低顺应性膀胱用A型肉毒杆菌毒素治疗。ATOMS植入术后可能出现OAB症状,但很少见,与失禁装置没有明确关联,而是与尿失禁相关的基础疾病和既往治疗有关。